Novel potent organoselenium compounds as cytotoxic agents in prostate cancer cells

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 24, 2007, Pages 6853-6859

  Plano, Daniel ^a   Sanmartín, Carmen ^a   Moreno, Esther ^a   Prior, Celia ^b   Calvo, Alfonso ^b   Palop, Juan Antonio ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cytotoxics; Organoselenium; Prostate

Indexed keywords

CARBAMIC ACID; CYTOTOXIC AGENT; ETOPOSIDE; IMIDOSELENOCARBAMATE DERIVATIVE; IMIDOTHIOCARBAMATE DERIVATIVE; ORGANOSELENIUM DERIVATIVE; SELENIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; EVALUATION RESEARCH; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; PROSTATE CANCER;

CARBAMATES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMIDES; MALE; MOLECULAR STRUCTURE; ORGANOSELENIUM COMPOUNDS; PROSTATIC NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 36049005326     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.022     Document Type: Article

References (41)

1. Sonn G.A., Aronson W., and Litwin M.S. Prostate Cancer Prostatic Dis. 8 (2005) 304
2. Brinkman M., Reulen R.C., Kellen E., Buntinx F., and Zeegers M.P. Eur. J. Cancer 42 (2006) 2463
3. Menter D.G., Sabichi A.L., and Lippman S.M. Cancer Epidem. Biomar. 9 (2000) 1171
4. Drake E.N. Med. Hypotheses 67 (2006) 318
5. Whanger P.D. Brit. J. Nutr. 91 (2004) 11
6. Klein E.A. Annu. Rev. Med. 57 (2006) 49
7. Silvera S.A.N., and Rohan T.E. Cancer Cause Control 18 (2007) 7
8. González C.A., and Salas-Salvado J. Brit. J. Nutr. 96 (2006) 587
9. Lee S.O., Chun J.Y., Nadiminty N., Trump D.L., Ip C., Dong Y., and Gao A.C. Prostate 66 (2006) 1070
10. Chun J.Y., Nadiminty N., Lee S.O., Onate S.A., Lou W., and Gao A.C. Mol. Cancer Ther. 5 (2006) 913
11. Goel A., Fuerst F., Hotchkiss E., Boland R., and Boland C.R. Cancer Biol. Ther. 5 (2006) 529
12. Smith M.L., Lancia J.K., Mercer T.I., and Ip C. Anticancer Res. 24 (2004) 1401
13. Rebsch C.M., Penna F.J., and Copeland P.R. Cell Res. 16 (2006) 940
14. Juang S.H., Lung C.C., Hsu P.C., Hsu K.S., Li Y.C., Hong P.C., Shiah H.S., Kuo C.C., Huang C.W., Wang Y.C., Huang L., Chen T.S., Chen S.F., Fu K.C., Hsu C.L., Lin M.J., Chang C.J., Ashendel C.L., Chan T.C., Chou K.M., and Chang J.Y. Mol. Cancer Ther. 6 (2007) 193
15. Zhao R., Domann F.E., and Zhong W. Mol. Cancer Ther. 5 (2006) 3275
16. Hu H.B., Jiang C., Schuster T., Li G.X., Daniel P.T., and Lu J.X. Mol. Cancer Ther. 5 (2006) 1873
17. Hu H.B., Jiang C., Li G.X., and Lu J.X. Carcinogenesis 26 (2005) 1374
18. Yamaguchi K., Uzzo R.G., Pimkina J., Makhov P., Golovine K., Crispen P., and Kolenko V.M. Oncogene 24 (2005) 5868
19. Li G.X., Hu H.B., Jiang C., Schuster T., and Lu J.X. Int. J. Cancer 120 (2007) 2034
20. Pinto J.T., Sinha R., Papp K., Facompore N.D., Desai D., and El-Bayoumy K. Int. J. Cancer 120 (2007) 1410
21. Husbeck B., Nonn L., Peehl D.M., and Knox S.J. Prostate 66 (2006) 218
22. Zhao H., Whitfield M.L., Xu T., Botstein D., and Brooks J.D. Mol. Biol. Cell 15 (2004) 506
23. Azrak R.G., Frank C.L., Ling X., Slocum H.F., Li F.Z., Foster B.A., and Rustum Y.M. Mol. Cancer Ther. 5 (2006) 2540
24. Gonzalez-Moreno O., Segura V., Serrano D., Nguewa P., Rivas J., and Calvo A. Int. J. Cancer 121 (2007) 1197
25. Sanmartín C., Echeverría M., Mendívil B., Cordeu L., Cubedo E., García-Foncillas J., Font M., and Palop J.A. Bioorg. Med. Chem. 13 (2005) 2031
26. Sanmartín C., Ardaiz E., Cordeu L., Cubedo E., García-Foncillas J., Font M., and Palop J.A. Lett. Drug Design Discov. 2 (2005) 341
27. Font M., Ardaiz E., Cordeu L., Cubedo E., García-Foncillas J., Sanmartín C., and Palop J.A. Bioorg. Med. Chem. 14 (2006) 1942
28. Echeverría M., Mendívil B., Cordeu L., Cubedo E., García-Foncillas J., Font M., Sanmartín C., and Palop J.A. Arch. Pharm. 339 (2006) 182
29. Sanmartín C., Font M., and Palop J.A. Mini-Rev. Med. Chem. 6 (2006) 639
30. Rao C.V., Wang C.Q., Simi B., Rodríguez J.G., Cooma I., El-Bayoumi K., and Reddy B.S. Cancer Res. 61 (2001) 3647
31. Shi C., Yu L., Yang F., Yan J., and Zeng H. Biochem. Biophys. Res. Commun. 309 (2003) 578
32. Meotti F.C., Stangherlin E.C., Zeni G., Nogueira C.W., and Rocha J.B.T. Environ. Res. 94 (2004) 276
33. Liu J.Q., Luo G.M., Ren X.J., Mu Y., Bai Y., and Shen J.C. Biochim. Biophys. Acta 1481 (2000) 222
34. Perrey D.A., Scannell M.P., Narla R.K., and Uckun F.M. Bioorg. Med. Chem. Lett. 10 (2000) 551
35. Ip C., and Ganther H.E. Carcinogenesis 13 (1992) 1167
36. 1H NMR (400 MHz, ...
37. 50-values in comparison to untreated control cells. PC-3 cells (human tumorigenic and metastatic prostate cancer cells) were obtained from American Type Culture Collection (ATCC), Manassas, USA, and cultured under standard conditions (Dulbecco's RPMI 1640 medium, with GlutamaxTM 1, Invitrogen) supplemented with 10% fetal bovine serum (Fetalclone III, SH30109.03, HYCLONE) and 1% Penicillin-Streptomycin (Invitrogen). RWPE-1 cells (non-tumorigenic human prostate cells) were also obtained from ATCC and cultured in keratinocyte-SFM Kit (Invitrogen) supplemented with 1% fetal bovine serum, Fetalclone III, SH30109.03, HYCLONE, and 1% Penicillin-Streptomycin (Invitrogen).
38. Dong Y., Zhang H., Hawthorn L., Ganther H.E., and Ip C. Cancer Res. 63 (2003) 52
39. Van Brussel J.P., Oomen M.A., Vosselbeld P.J.M., Wiemer E.A.C., Sonneveld P., and Mickisch G.H.J. BJU Int. 93 (2004) 1333
40. Pickering I.J., Wright C., Bubner B., Ellis D., Persans M.W., Yu E.Y., George G.N., Prince R.C., and Salt D.E. Plant Physiol. 131 (2003) 1460
41. El-Bayoumi K., Sinha R., Pinto J.T., and Rivlin R.S. J. Nutr. 136 (2006) 864S